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Abstract
Background—Recurrent infection with the hepatitis C virus (HCV) after liver transplantation is 
associated with decreased graft and patient survival. Achieving sustained virological response 
(SVR) with antiviral therapy improves survival. Because interferon-based therapy has limited 
efficacy and is poorly tolerated, there has been rapid transition to interferon-free direct-acting 
antiviral (DAA) regimens. Herein the experience with DAAs in the treatment of post-transplant 
genotype 1HCV from a consortium of community and academic centers (HCV TARGET) is 
described.
Methods—Twenty-one of the 54 centers contributing to the HCV TARGET consortium 
participated in this study. Enrollment criteria included positive post-transplant HCV RNA prior to 
treatment, HCV genotype 1, and documentation of use of a simeprevir/sofosbuvir (SMV/SOF) 
containing DAA regimen. Safety and efficacy were assessed. SVR was defined as undetectable 
HCV RNA 64 days or later after cessation of treatment.
Results—A total of 162 patients enrolled in HCV-TARGET started treatment with SMV/SOF 
with or without ribavirin following liver transplantation. The study population included 151 
patients treated with these regimens for whom outcomes and safety data were available. The 
majority of the 151 patients were treated with sofosbuvir and simeprevir alone (n=119, 78%) or 
with ribavirin (n=32, 22%), The duration of therapy was 12 weeks for most patients, although 15 
patients received 24 weeks of treatment. Of all patients receiving SOF/SIM +/− Ribavirin, 133/151 
(88%) achieved SVR12 and 11 relapsed (7%). One patient had virologic breakthrough (n=1) and 6 
patients were lost to post treatment follow up. Serious adverse events occurred in 12%; 3 patients 
(all cirrhotic) died due to aspiration pneumonia, suicide, and multi-organ failure. One experienced 
liver transplant rejection.
Conclusions—Interferon-free DAA treatment represents a major improvement over prior 
interferon-based therapy. Broader application of these and other emerging DAA regimens in the 
treatment of post-transplant hepatitis C is warranted.
INTRODUCTION
Recurrent hepatitis C virus (HCV) is the leading cause of graft loss and death in HCV-
infected liver transplant (LT) recipients (1, 2). Achieving sustained virological response 
(SVR) with antiviral therapy improves post-LT survival (3–7), and may lead to stabilization 
or improvement in histology (8–15) and diminished risk of hepatic decompensation (4, 12).
Until very recently, interferon-based therapy was the only treatment option and rates of SVR 
in post-transplant patients with HCV GT1 infection were only 20 to 30%. Addition of either 
telaprevir or boceprevir doubled rates of SVR, but was associated with significant drug-drug 
interactions, profound anemia, rash, intolerability, complex management, and excessive 
resource utilization (3, 10, 13, 16–20). The U.S. Food and Drug Administration (FDA) and 
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European Medicines Agency (EMA) approvals of sofosbuvir (SOF) and simeprevir (SMV) 
in 2013 heralded a new era in DAA therapy of HCV-related liver disease. The first, FDA-
approved interferon-free regimen, SOF/RBV for HCV genotypes 2 and 3, was introduced 
and this combination was immediately tested in liver recipients with recurrent hepatitis C. 
The rate of SVR was 70%. At about the same time a Phase 2 study, COSMOS, achieved 
rates of SVR from 93% to 100% using SMV/SOF, even in treatment experienced patients 
with cirrhosis. Although only small numbers of patients were studied and SOF and SMV 
were initially FDA and EMA approved in combination with PEG/RBV for GT1, the 
COSMOS data influenced the American Association for the Study of Liver Diseases/
Infectious Diseases Society of America (AASLD/IDSA) and the European Association for 
the Study of the Liver (EASL) to recommend SMV/SOF in combination for the treatment of 
patients with post-transplant recurrence of GT1 HCV. The FDA later approved the 
combination of SMV/SOF on November 6, 2014 for treatment of GT1 non-transplant 
patients. As a result, transplant physicians quickly adopted the use of not only SOF/RBV but 
also the SMV/SOF combination (21). Limited data with both SOF/ledipasvir as well as the 
combination of ombitasvir/paritaprevir/ritonavir and dasabuvir in post-transplant trials 
indicate high efficacy and tolerability of all oral regimens (22–24). However, real-world 
evaluation of the efficacy and safety of all-oral therapy for post-transplant patients is limited.
HCV-TARGET is a multicenter consortium of both academic and community liver centers 
that collect post-approval prospective treatment data on SVR rates and other clinical 
outcomes of new HCV regimens. Herein, we describe the safety and efficacy of simeprevir 
(SMV) and sofosbuvir (SOF) in post-LT patients infected with HCV genotype 1 from 21 
transplant centers. This experience represents the most comprehensive real-world study in 
post-LT patients to date.
MATERIALS AND METHODS
Study population and design
HCV-TARGET is a longitudinal, observational study in chronic hepatitis C patients from a 
consortium of academic (n=39) and community (n=15) medical centers. Since 2011, 
consented patients prescribed HCV treatment as part of routine clinical practice at one of the 
participating medical centers have been enrolled in HCV-TARGET. The cohort of patients 
included in this analysis were liver transplant (LT) patients enrolled at 21 participating 
medical centers which were also transplant centers. The patients in the current study were 
infected with HCV genotype 1, were 18 or more years old, and started treatment with SMV
+SOF with or without RBV prior to 10 October 2014.
Treatments
Treatment was chosen and administered per local standards at the study sites; the study 
protocol did not define specific treatment populations, regimens, dosing, duration, or safety 
management guidelines. The decision to initiate HCV treatment and the selection of the 
HCV treatment regimen (with or without ribavirin) was solely the responsibility of the 
treating clinician and his or her patient; this was a non-random process in which a regimen 
was selected for an individual patient.
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Data was captured from sequentially enrolled patients using a common database that utilized 
novel, standardized source data abstraction previously described (25). In brief, a centralized 
team of trained coders reviewed all redacted medical records obtained from participating 
sites for data entry. Throughout treatment and during post-treatment follow-up, 
demographic, clinical, adverse event, and virologic data were collected. The assay used for 
HCV RNA quantification/detection was specific to the treatment center. Independent data 
monitors systematically reviewed the data entries for completeness and accuracy. All records 
were screened for extreme or unlikely values and verified/resolved with additional queries. 
The choice of and management of immunosuppression and graft rejection was also at the 
discretion of the investigators. Pre- and end-treatment calcineurin inhibitor doses were 
recorded in addition to the use of mammalian target of rapamycin (mTOR) inhibitors, 
mycophenolate mofetil/mycophenolic acid and steroids. This study was approved by the 
local Institutional Review Boards at all participating sites. Participants provided written 
informed consent according to local IRB policies.
Primary Outcomes—The primary endpoint was sustained virological response 12 weeks 
post-therapy (SVR12) defined as HCV RNA below level of quantitation or undetected at 
least 64 days after treatment was discontinued. HCV RNA levels were measured according 
to local practice, usually prior to treatment initiation at weeks 4, 8, and at the end of 
treatment and 4 and 12 weeks after treatment discontinuation.
Secondary endpoints included rates of relapse, treatment discontinuation, and safety 
including episodes of rejection, rates of anemia, renal dysfunction, hepatic decompensation, 
and death. The efficacy and safety cohorts included all patients who received HCV therapy 
and for whom an outcome (SVR, virological failure, lost to follow-up) was recorded.
Definitions
Cirrhosis—The presence of cirrhosis was defined by biopsy and/or a combination of 
clinical, laboratory, and imaging criteria established a priori (27). Patients were determined 
to have cirrhosis if they had: 1) evidence of stage 4 fibrosis by liver biopsy at any time prior 
to therapy, or 2) evidence of stage 3 fibrosis by liver biopsy at any time prior to therapy plus 
any of the following criteria: platelets count <140,000 per µl, presence of esophageal varices 
on esophagogastroduodenoscopy, evidence of cirrhosis and/or portal hypertension and/or of 
ascites by imaging studies, FibroSure® or Fibrotest®, transient elastography, or equivalent 
compatible with stage 4 fibrosis, or 3) in the absence of liver biopsy, any two of the 
following criteria: platelets count <140,000 per µl, presence of esophageal varices on 
esophagogastroduodenoscopy, evidence of cirrhosis and/or portal hypertension and/or 
ascites by imaging studies, FibroSure® or Fibrotest®, transient elastography, or equivalent 
compatible with stage 4 fibrosis.
Adverse events (AE)—1) Any event that occurred on treatment was collected and 
reported regardless of the need or lack thereof for a prescription medication or a dose 
reduction or discontinuation of HCV treatment.
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Anemia—Defined as the presence of at least one of the following: 1) Adverse Event of 
Anemia as reported by investigator; 2) administration of hematologic growth factors was 
documented; or 3) transfusion occurred.
Hepatic decompensation during therapy—Patient experienced one or more of the 
following AEs: 1) hepatic decompensation was listed as an AE by the healthcare 
practitioner; 2) new onset of hepatic encephalopathy; 3) new onset spontaneous bacterial 
peritonitis; 4) new onset variceal hemorrhage; 5) new onset ascites; 6) new onset hepatic 
hydrothorax or 7) patient received a new prescription for a medication to treat one of the 
above indications (1–5).
Serious adverse event (SAE)—An AE that required hospitalization or met criteria for 
expedited reporting per FDA form MEDWATCH 3500.
Statistical analyses
The unadjusted rate of SVR, relapse, treatment completion and frequency of AEs were 
calculated for the entire study population and for sub-populations. Confidence intervals of 
unadjusted rates were calculated using exact binomial methods. Measures of association 
between baseline covariates and SVR where estimated with conditional logistic regression 
models stratified on regimen. The set of baseline covariates were selected a priori based 
upon a consensus of clinical expertise. Relative risk estimates of SVR (SOF + SMV to SOF 
+ SMV + RBV) were calculated using Mantel–Haenszel methods. Multiple imputation 
methods were used to account for missing data in both the conditional logistic regression 
models and the relative risk calculations. Analyses were performed using SAS software 




A total of 151 post-LT patients with genotype 1 met the inclusion criteria. Baseline 
characteristics for all 151 patients are shown in Table 1. The mean age for all participants 
was 61 years (range 46–78 years) and 74% were male. Seventy six percent of the patients 
were Caucasian, 9% African American, 3% Asian and 13% were of other race or 
unreported. 15% were of Hispanic ethnicity. Mean total bilirubin was 1.6 mg/dl (range 0.3–
21.0 mg/dl) with mean serum albumin of 3.8 g/dl (range 2.0–4.9 g/dl). Mean platelet count 
was 140,000µl (Range: 44,000 to 460,000/µl). The majority of patients had HCV genotype 
1a (58%), were treatment-experienced (56%), and 7% had failed prior treatment with either 
telaprevir- or boceprevir-based therapy, either prior to or following transplant (timing of 
treatment was not collected). Allograft cirrhosis had developed in 64% of the patients (14 
were biopsy proven) and 58% of the cirrhotic patients had evidence of clinical 
decompensation (Table 1). Child-Pugh score was not collected due to the subjective nature 
of ascites and encephalopathy grading and reporting.
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The treatment duration was 12 weeks for the majority of the cohort, however 15/151 (10%) 
patients received 24 weeks. Only 5 patients (3%) had early treatment discontinuation, with 
one patient stopping for lack of efficacy, 4 for adverse events and/or death. Ribavirin dosing 
was per center preference with a median starting dose of 800 mg/day.
Treatment response
Of 151 patients in the current analysis, 119 (78%) were treated with SMV+SOF without 
RBV and 32 (22%) were treated with SMV+SOF+RBV (Table 2). SVR12 was achieved by 
88% (133/151) of those treated with SMV/SOF + RBV. SVR12 results for subgroups of 
patients are shown in Table 3. Patients with genotype 1a treated with SMV/SOF achieved 
SVR12 in 57/67 (85%) compared to 30/32 (94%) of those with genotype 1b. In general, 
patients with cirrhosis had numerically lower rates of SVR compared to non-cirrhotic 
patients (Table 3). Because post-transplant patients may have low platelet counts for reasons 
other than cirrhosis, the unadjusted SVR was calculated excluding 19 subjects who would be 
reclassified if low platelet count was not a criteria for determining cirrhosis and there were 
no substantial differences (data not shown). Treatment failures were mostly due to relapse 
(7%) although viral breakthrough did occur in one patient.
Predictors of Treatment Response
Multivariable models were limited to the 129 patients that (a) were treated with SMV/SOF ± 
RBV for a duration of 14 or fewer weeks (to capture those with intended duration of therapy 
of 12 weeks) and (b) completed treatment or discontinued due to virological failure. 
Conditional logistic regression models of SVR12 stratified by regimen did not identify any 
factors with statistically significant association with SVR12. While not reaching the level of 
statistical significance, the estimated association between SVR12 and some factors such as 
higher levels of baseline hemoglobin (OR 2.5, 95% CI 0.9–6.9 suggest possible correlation 
with higher rates of SVR (Figure 1).
Comparative Effectiveness of SMV/SOF + RBV and SMV/SOF
The sample size constraints prohibit a comparative effectiveness analysis that controls for all 
factors that affect regimen choice. As such, the comparative effectiveness estimates in the 
129 patients who (a) were treated with SMV/SOF with and without RBV for a duration of 
14 or fewer weeks and (b) completed treatment or discontinued due to virological failure are 
reported. Further, an adjustment for previous treatment status was made because of its strong 
association with regimen choice. Overall, the estimated SVR rate was very similar between 
the two regimen choices when controlling for previous treatment experience. The probability 
of SVR in SMV+SOF was 0.97 (95% CI: 0.79, 1.18) that of SMV+SOF+RBV. The relative 
risk (RR) estimates comparing SMV+SOF+RBV to SMV+SOF in various subgroups are 
reported in Figure 2; the estimates of RR when controlling for previous treatment indicate 
that the addition of RBV had no detectable impact on SVR.
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The most common adverse event was fatigue (25%), followed by headache (19%), any 
infection (15%), rash/pruritus (14%), influenza like illness (12%), nausea/vomiting (11%), 
and anemia (11%); (Table 4). The mean hemoglobin at treatment initiation was 13.0 g/dL 
(range 7.9 – 17.7). Anemia was reported as an AE in 11% of the total patients, which varied 
dramatically by treatment regimen: 38% of SMV/SOF plus RBV, and 3% of SMV/SOF 
treated patients. Only 1 SAE for anemia was reported (SMV/SOF). The mean change in 
hemoglobin in the SMV+SOF+RBV group was −1.2 g/dL, with −0.1 g/dL mean change 
reported in the SMV/SOF group (Table 5). The use of erythropoietin and transfusion for 
anemia was low at 3% for both. RBV dose reduction was required in 8 (5%) patients, and 
RBV discontinuation was only necessary in 1 patient (Table 5).
Hepatic decompensation occurred in 8 patients. All had known cirrhosis at baseline and 5 
had a baseline MELD of 10 or greater (of 8 patients with known baseline MELD). Three 
patients died, 2 of which had cirrhosis (pre-treatment MELD of 8 and 26). Deaths were 
attributed to hepatic and renal failure in one, suicide in another (occurred during treatment) 
and aspiration pneumonia (occurred post-treatment) in third patient- all with cirrhosis. Renal 
failure and aspiration pneumonia were indicated as being related to treatment by the treating 
physician. There was only one episode of acute rejection reported. Acute kidney injury or 
failure occurred in 3 patients taking SMV+SOF+RBV, and in 8 patients taking SMV+SOF. 
Overall mean creatinine change was small, 0.0 mg/dL (range −0.9 to 0.7 mg/dL). Mean total 
bilirubin changes were small −0.4 mg/dL, though there was a broad range −8.0 to 2.5 
mg/dL. In the 16 patients treated with cyclosporine on SMV/SOF the mean increase in 
creatinine was −0.01 mg/dL, with a range from −0.84 to 0.31 mg/dL.
Immunosuppression
Of 151 patients, 137 (91%) patients were on calcineurin inhibitors [121 tacrolimus, 15 
cyclosporine and one received both] and 23 (15%) on mTOR inhibitors at the start of 
antiviral therapy. In addition, 70 patients (46%) were on mycophenolate mofetil or 
mycophenolic acid. One patient was on maintenance steroids (not shown in table). Changes 
in immunosuppression dosages on average were small, with delta mean changes in 
tacrolimus, cyclosporine, and everolimus/sirolimus of respectively 0 mg, −17 mg, and 0 mg 
(Table 4). There were no safety signals for the concomitant use of cyclosporine and 
simeprevir, though the number of patients is small.
DISCUSSION
Patients with recurrent HCV after liver transplantation have the most urgent need for 
effective antiviral therapy due to their potential for rapidly progressive fibrosis, graft loss, 
and death. However, treatment with interferon-based regimens has been difficult due to 
safety concerns and inadequate efficacy. Potent, well-tolerated, IFN-free therapy promises to 
greatly improve efficacy and expand treatment options for these patients in great need for 
cure of their HCV infection. Preliminary reports from phase 2 clinical trials suggest that all-
oral regimens are effective in liver transplant recipients (23, 26). The present study reports 
the safety and efficacy of interferon-free all oral treatment in a real world cohort of post-LT 
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patients with recurrent genotype 1 HCV, many of whom had more severe disease than in the 
clinical trials or other reported studies and had failed prior PI based triple therapy regimens.
The combination of sofosbuvir and simeprevir for the treatment of HCV recurrence after 
liver transplantation is attractive due to the low potential for drug-drug interactions (27, 28). 
In our study, there did not appear to be any safety consideration for the use of simeprevir 
with either cyclosporine or decompensated cirrhosis, though the small numbers limit 
conclusions and in the absence of a control group it is impossible to exclude a potential drug 
effect in the patients who had further hepatic decompensation on therapy. Nevertheless, it 
should be noted that the use of simeprevir is not recommended in patients with 
decompensated cirrhosis (CP-B and C cirrhosis) (29).
SVR12 was achieved in 88% of this study cohort. This is substantially higher than the rates 
reported for peginterferon and RBV dual therapy or protease inhibitor-based triple therapy 
(19, 20, 30). Additionally the safety profile was excellent with a low rate of AE and SAE 
and extremely low rate of treatment discontinuation (<5%). This is similar to the rates of 
SVR seen in the Mayo Clinic experience with SOF/SMV of 90% in 105 patients and the 
University of Miami experience, which achieved SVR12 of 93% in 61 patients (31–33). It is 
important to note that our series included a more advanced population with a higher rate of 
cirrhosis (64% versus 30% or less in those 2 studies) with more patients with 
decompensated cirrhosis). We did see one episode of rejection with IFN-free therapy, 
previously a concern with IFN-based therapy (34).
Of the baseline covariates selected a priori as potential predictors of SVR12, none exhibited 
a statistically significant association with the outcome. This is likely a result of high 
observed SVR rates that requires a larger sample to detect differences. However, among 
many of the potential predictors, the direction of the estimated association is consistent with 
prior expectations. As one example, the estimated association of SVR12 and cirrhosis status 
indicates that non-cirrhotic patients have higher SVR rates than their cirrhotic counterparts. 
Unfortunately Q80K mutation data was only available for 19 patients (not shown in table) 
and RAV data was not collected, so the impact of Q80K or baseline RAV’s on treatment 
response could not be assessed, however the response rate was higher in GT 1b than GT1a 
patients (93% vs 85%), similar to what was seen in the single center studies, neither of 
which collected data on Q80K mutations (31–33).
The current study also represents the largest report of safety and efficacy in a diverse 
population of real-world patients treated with all-oral therapy post-LT outside of a tightly 
controlled clinical trial. Several smaller studies of post-LT patients treated with dual 
combinations of sofosbuvir, a NS5A replication complex inhibitor (ledipasvir or daclatasvir) 
and simeprevir, have been reported (23, 35, 36). These studies used 12 or 24 weeks of 
therapy and included RBV. In the present study patients treated with or without RBV had 
similar rates of SVR. Of note, recent FDA approval of SMV/SOF for treatment of genotype 
1 HCV was for 24 weeks in patients with cirrhosis, although too few patients in our study 
were treated for 24 weeks to determine if extended duration therapy improved outcome. 
Higher rates of relapse in advanced fibrosis patients (F3 and F4) were also seen with 12 
weeks of SMV+SOF+RBV in other studies (31, 32). It is anticipated that, pre-emptive or 
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early post-LT HCV therapy will lead to most patients being treated before they develop 
advanced fibrosis/cirrhosis and thus obviate the future need for extended duration of therapy.
Serious adverse events occurred in 12% of the present cohort, and included anemia, renal 
dysfunction, liver decompensation and death. Much of this may represent progression of 
disease despite antiviral therapy as all treated patients were included and there were no 
exclusions based on severity of disease. This has been seen in the compassionate use 
programs for SOF and daclatasvir (22, 35). However, whether clinical decompensation can 
occur with antiviral clearance in the absence of peginterferon remains to be determined.
In a phase 2 open-label study of LT recipients who received SOF+RBV for 24 weeks, 100% 
of patients achieved RVR and EOTR, while only 70% achieved SVR12 (26). This study 
included patients with genotypes 2–4, and 40% had recurrent cirrhosis but no patients had 
evidence of hepatic decompensation. In the SOF compassionate use program, patients with 
either severe early recurrence within the first year or recurrent cirrhosis were treated with 
24–48 weeks of SOF/RBV (22). Of the patients who did not undergo retransplantation 
(n=12), SVR rate was 59%, although it was higher (73%) in the 48 patients with severe 
cholestatic hepatitis. Fortunately, the majority (57%) experienced clinical improvement, but 
SAE’s occurred in 47%; 18% had hepatic decompensation and 13% died.
Another all oral regimen, ombitasvir/paritaprevir/ritonavir plus dasabuvir plus RBV for 24 
weeks, was studied in a Phase 2 open-label study in stable noncirrhotic (F0-F2) post-LT 
patients >1 year after transplant (23). The regimen was extremely effective with a SVR rate 
of 97% in 34 patients with a low rate of adverse events other than RBV induced anemia. 
However, the significant drug-drug interactions seen secondary to ritonavir boosting 
required close monitoring and adjustment of tacrolimus and cyclosporine levels. In addition, 
efficacy and safety was not established for shorter duration therapy, more advanced fibrosis/
cirrhosis, or in a real world setting. Another all oral regimen under study is simeprevir in 
combination with daclatasvir and ribavirin. This study is limited to patients on tacrolimus-
based immunosuppression due to the known drug interaction between simeprevir and 
cyclosporine. Preliminary results indicate a 90–93% SVR4 rate and good tolerability, though 
SVR 12 is not yet available and the number of patients with advanced liver disease (F3–4) is 
limited (37).
SOF/LDV plus RBV has been studied in the post-LT population across a broader range of 
liver disease severity including cirrhosis and decompensation (36). Patients with earlier stage 
disease and those with cirrhosis had similar SVR12 rates of 96–98% regardless of treatment 
duration (12 vs. 24 weeks). SVR12 decreased to 83–85% in Child class B cirrhotic patients 
and 60–67% in Child class C cirrhosis, although the number of patients in the latter group 
was very small. All regimens studied to date used RBV in post-LT patients and the 
development of anemia was more profound and frequent compared to the non-transplant 
setting.
Although our study benefits from its large, multicenter, prospective, real world experience, it 
has some methodological limitations. The inclusion and exclusion of patients and treatment 
regimen chosen was not standardized. However the safety profile in this real world cohort, 
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where there were expanded indications of advanced liver disease, was excellent and coupled 
to high efficacy. The immunosuppression and HCV treatment regimens also varied between 
patients and centers likely leading to heterogeneity, which is compounded by a relatively 
small sample size in the subgroups; yet there were no significant issues with rejection. Rare 
renal events potentially related to HCV therapy were reported but are difficult to interpret in 
the absence of an untreated control group. In this study cohort, 137 patients (91%) had been 
treated with a calcineurin inhibitor (CNI) of tacrolimus (122, 80%) or cyclosporine (16, 
10%). (One patient recorded treatment with both) The SVR rate among patients who 
received tacrolimus was 91% while the rate among patients receiving cyclosporine was 80%. 
Because the selection of a CNI drug is influenced by factors that may also influence SVR, 
we do not provide a statistical comparison of the SVR rates in the two groups as such a 
comparison may be biased by treatment choice. Only 16 patients were treated with 
cyclosporine, and given the 4.81-fold increase in SMV levels expected in cyclosporine 
treated patients, this combination remains not recommended (38). Nevertheless, in aggregate 
this represents a real world experience in the treatment of diverse post-transplant patients 
including those with decompensated cirrhosis, and this heterogeneity enhances the study’s 
generalizability. Finally, follow up for the patients was generally limited to SVR12, thus, the 
long-term benefits of SVR such as histological stabilization or regression of fibrosis, 
prevention of hepatic decompensation and improved survival remains under investigation.
In summary, substantially higher SVR12 rates are achieved with SMV/SOF-based anti-HCV 
therapy post-LT than previously reported for IFN-based therapy. While the optimal choices 
of all oral DAA regimens for HCV treatment post-LT is likely to rapidly evolve in the 
coming years, SMV/SOF is an effective, well tolerated, all-oral and potentially RBV-free 
choice for recurrent HCV with minimal drug-drug interactions with common 
immunosuppressive agents. As more clinical trials with safe, all oral, short courses of DAA 
are performed in transplant patients, all post-LT patients will likely be treated either pre-, 
peri-, or shortly after liver transplantation.
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EOTR end of treatment response
eRVR extended rapid virologic response
GCSF granulocyte colony stimulating factor
Brown et al. Page 10













HCV Hepatitis C virus
LT liver transplantation
mTOR mammalian target of rapamycin
MMF mycophenolate mofetil
MPA mycophenolate acid
NPV negative predictive value
P-IFN pegylated interferon
PPV positive predictive value
PI protease inhibitor
RVR rapid virologic response
SVR sustained virologic response
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Odds Ratio Estimates of SVR12 Controlling for Regimen Choice. (Excludes non-virological 
failures.)
Odds ratios are calculated from conditional logistic regression models stratified on regimen. 
Each line represents an estimate from a distinct model in which SVR is the outcome, the 
predictor is the covariate, and regimen is the stratum.
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Relative Risk of SVR12 (SOF+SMV+RBV reference). (Excludes non-virological failures.)
Relative risks are Mantel-Haenszel estimates stratified on previous treatment (experienced v. 
naive). Previous treatment is a predictor of regimen choice (SOF+SMV v. SOF+SMV
+RBV) among patients which completed treatment or discontinued due to virological 
reasons. (Relative risk estimates for Tx experienced and Tx Naive are not stratified.)
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Table 1








Mean age (range), y 62 (49–78) 60 (46–71) 61 (46–78)
Male sex, n (%) 86 (72.3) 26 (81.3) 112 (74.2)
Race, n (%)
  White 87 (73.1) 27 (84.4) 114 (75.5)
  Black 12 (10.1) 2 (6.3) 14 (9.3)
  Asian 3 (2.5) 1 (3.1) 4 (2.6)
  Other/missing 17 (14) 2 (6) 19 (13)
Ethnicity Hispanic,1 n (%) 19 (16.0) 3 (9.4) 22 (14.6)
Mean years since LT (range) 5 (0–23) 4 (0–14) 5 (0–23)
Mean ALT (range), mean IU/l 107 (10–733) 118 (26–461) 109 (10–733)
Mean total bilirubin (range), mg/dl 1.3 (0.3–21.0) 2.5 (0.3–14.0) 1.6 (0.3–21.0)
Mean albumin (range), g/dl 3.8 (2.2–4.9) 3.5 (2.0–4.3) 3.8 (2.0–4.9)
Mean hemoglobin (range), g/dl 13.3 (8.4–17.7) 12.6 (7.9–16.7) 13.2 (7.9–17.7)
Mean platelet count (range) (×103) per µl 137 (44–460) 151 (54–245) 140 (44–460)
History of cirrhosis, n (%) 74 (62.2) 23 (71.9) 97 (64.2)
History of liver decompensation, n (%) 46 (38.7) 14 (43.8) 60 (39.7)
Presence of diabetes, n (%) 48 (40.3) 18 (56.3) 66 (43.7)
HCV genotype, n (%)
  1a 67 (56.3) 20 (62.5) 87 (57.6)
  1b 32 (26.9) 10 (31.3) 42 (27.8)
  1, subtype unspecified 20 (16.8) 2 (6.3) 22 (14.6)
Prior HCV treatment, n (%)
  Treatment naïve 57 (47.9) 9 (28.1) 66 (43.7)
  Prior PI failure 8 (6.7) 3 (9.4) 11 (7.3)
Immunosuppression, n (%)
  Tacrolimus 98 (82.4) 24 (75.0) 122 (80.8)
  Cyclosporine 15 (12.6) 1 (3.1) 16 (10.6)
  Everolimus/ Sirolimus 12 (10.1) 11 (34.4) 23 (15.2)
  MMF/MPA 51 (42.9) 19 (59.4) 70 (46.4)
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ALT, alanine aminotransferase; HCV, hepatitis C virus, MMF: mycophenolate mofetil; MPA: mycophenolic acid























Completed therapy 115 (96.6) 31 (96.9) 146 (96.7)
Discontinued earlya 4 (3.4)b 1 (3.1)c 5 (3.3)
  Adverse event 3 (2.5) 1 (3.1) 4 (2.6)
  Lack of efficacy 1 (0.8) 0 (0.0) 1 (0.7)
Lost to post treatment follow-upd 4 (3.4) 2 (6.2) 6 (4.0)
a
Includes 3 patients who died
b
Cause of death: Multiorgan failure, aspiration pneumonia
c
Cause of death: Suicide
d
Lost to follow-up were included in SVR12 assessment and counted as treatment failures




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Most common Adverse Events, n (%)
  Fatigue 31 (26.1) 7 (21.9) 38 (25.2)
  Headache 20 (16.8) 8 (25.0) 28 (18.5)
  Infections and infestations 20 (16.8) 2 (6.2) 22 (14.6)
  Rash/Pruritus 17 (14.3) 4 (12.5) 21 (13.9)
  Influenza like illness 12 (10.1) 6 (18.8) 18 (11.9)
  Nausea/Vomiting 13 (10.9) 4 (12.5) 17 (11.3)
  Anemia 4 (3.4) 12 (37.5) 16 (10.6)
Total patients with reported AEs 86 (72.3) 28 (87.5) 114 (75.5)
All Serious Adverse Events, n (%)
  Renal failure acute 3 (2.5) 1 (3.1) 4 (2.7)
  Abdominal pain upper 2 (1.7) 0 (0.0) 2 (1.3)
  Infections 2 (1.7) 0 (0.0) 2 (1.3)
  Hepatic decompensation 1 (0.8) 1 (3.1) 2 (1.3)
  Anemia 1 (0.8) 0 (0.0) 1 (0.7)
  Hepatic arteriovenous malformation 0 (0.0) 1 (3.1) 1 (0.7)
  Nausea 0 (0.0) 1 (3.1) 1 (0.7)
  Esophageal stenosis 0 (0.0) 1 (3.1) 1 (0.7)
  Edema 1 (0.8) 0 (0.0) 1 (0.7)
  Pyrexia 1 (0.8) 0 (0.0) 1 (0.7)
  Cholangiolitis 0 (0.0) 1 (3.1) 1 (0.7)
  Hepatic enzyme increased 1 (0.8) 0 (0.0) 1 (0.7)
  Dehydration 0 (0.0) 1 (3.1) 1 (0.7)
  Hyperglycemia 1 (0.8) 0 (0.0) 1 (0.7)
  Hypervolemia 1 (0.8) 0 (0.0) 1 (0.7)
  Suicide 0 (0.0) 1 (3.1) 1 (0.7)
  Pneumonia aspiration 1 (0.8) 0 (0.0) 1 (0.7)
  Pulmonary embolism 1 (0.8) 0 (0.0) 1 (0.7)
  Hematoma 1 (0.8) 0 (0.0) 1 (0.7)
Total patients with reported SAEs 12 (10.1) 6 (18.8) 18 (11.9)
Mean change in laboratory values, baseline to end of treatment
  Creatinine change, mean (range) 0.01 (−0.84,+0.68) −0.06 (−0.85,+0.33) −0.01 (−0.85,+0.68)
  Total Bilirubin change, mean (range) −0.2 (−5.3,+2.5) −1.2 (−8.0,+0.9) −0.4 (−8.0,+2.5)
Immunosuppression dose change, mean (range)
  TAC 0 (−6,+2) 0 (−2,+4) 0 (−6,+4)




















  CSA −18 (−275,+125) −17 (−275,+125)
  Everolimus/ Sirolimus 0 (−2,+0.5) 0 (−1, +2) 0 (−2,+2)
  MMF/MPA −20 (−1000,+1000) 104 (0–750) 14 (−1000,+1000)






















AE Anemia, n (%) 4 (3.4) 13 (40.6) 17 (11.3)
SAE Anemia, n (%) 1 (0.8) 0 (0.0) 1 (0.7)
Hemoglobin change, delta mean (range) −0.1 (−4.9,+3.1) −1.2 (−6.9,+4.1) −0.4 (−6.9,+4.1)
Anemia management, n (%)
  Ribavirin dose reduction/interruption 0 (0.0) 8 (25.0) 8 (5.3)
  Epoietin use 0 (0.0) 5 (15.6) 5 (3.3)
  Blood transfusion 2 (1.7) 3 (9.4) 5 (3.3)
  Ribavirin discontinuation 0 (0.0) 1 (3.1) 1 (0.7)
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